Suppr超能文献

心脏疾病中的线粒体功能障碍及治疗策略

Mitochondrial Dysfunction in Cardiac Diseases and Therapeutic Strategies.

作者信息

Huang Yafei, Zhou Bingying

机构信息

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, 167 North Lishi Road, Xicheng District, Beijing 100037, China.

出版信息

Biomedicines. 2023 May 22;11(5):1500. doi: 10.3390/biomedicines11051500.

Abstract

Mitochondria are the main site of intracellular synthesis of ATP, which provides energy for various physiological activities of the cell. Cardiomyocytes have a high density of mitochondria and mitochondrial damage is present in a variety of cardiovascular diseases. In this paper, we describe mitochondrial damage in mitochondrial cardiomyopathy, congenital heart disease, coronary heart disease, myocardial ischemia-reperfusion injury, heart failure, and drug-induced cardiotoxicity, in the context of the key roles of mitochondria in cardiac development and homeostasis. Finally, we discuss the main current therapeutic strategies aimed at alleviating mitochondrial impairment-related cardiac dysfunction, including pharmacological strategies, gene therapy, mitochondrial replacement therapy, and mitochondrial transplantation. It is hoped that this will provide new ideas for the treatment of cardiovascular diseases.

摘要

线粒体是细胞内合成三磷酸腺苷(ATP)的主要场所,为细胞的各种生理活动提供能量。心肌细胞中线粒体密度很高,并且在多种心血管疾病中均存在线粒体损伤。在本文中,我们结合线粒体在心脏发育和体内平衡中的关键作用,描述了线粒体心肌病、先天性心脏病、冠心病、心肌缺血-再灌注损伤、心力衰竭和药物性心脏毒性中的线粒体损伤。最后,我们讨论了目前旨在减轻与线粒体功能障碍相关的心脏功能障碍的主要治疗策略,包括药理学策略、基因治疗、线粒体替代疗法和线粒体移植。希望这将为心血管疾病的治疗提供新思路。

相似文献

1
Mitochondrial Dysfunction in Cardiac Diseases and Therapeutic Strategies.
Biomedicines. 2023 May 22;11(5):1500. doi: 10.3390/biomedicines11051500.
2
Mitochondrial disorder and treatment of ischemic cardiomyopathy: Potential and advantages of Chinese herbal medicine.
Biomed Pharmacother. 2023 Mar;159:114171. doi: 10.1016/j.biopha.2022.114171. Epub 2023 Jan 13.
3
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer.
J Transl Med. 2023 Sep 19;21(1):635. doi: 10.1186/s12967-023-04498-5.
5
Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association.
Int J Mol Sci. 2021 Jan 9;22(2):614. doi: 10.3390/ijms22020614.
6
Myocardial Ischemia-Reperfusion Injury: Therapeutics from a Mitochondria-Centric Perspective.
Cardiology. 2021;146(6):781-792. doi: 10.1159/000518879. Epub 2021 Sep 21.
7
Mitochondrial Quality Control in Cardiomyocytes: A Critical Role in the Progression of Cardiovascular Diseases.
Front Physiol. 2020 Mar 27;11:252. doi: 10.3389/fphys.2020.00252. eCollection 2020.
9
Mitochondrial scenario: roles of mitochondrial dynamics in acute myocardial ischemia/reperfusion injury.
J Recept Signal Transduct Res. 2021 Feb;41(1):1-5. doi: 10.1080/10799893.2020.1784938. Epub 2020 Jun 25.

引用本文的文献

4
5
Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.
MedComm (2020). 2025 Mar 10;6(3):e70134. doi: 10.1002/mco2.70134. eCollection 2025 Mar.
6
Mitochondrial Dysfunction in Cardiac Disease: The Fort Fell.
Biomolecules. 2024 Nov 29;14(12):1534. doi: 10.3390/biom14121534.
7
NRIP1 is a downstream target of YY1 in promoting OGD/R-induced H9c2 cardiomyocyte injury and mitochondrial dysfunction.
Histol Histopathol. 2025 May;40(5):773-784. doi: 10.14670/HH-18-820. Epub 2024 Sep 24.
8
Mitochondrial complex-1 as a therapeutic target for cardiac diseases.
Mol Cell Biochem. 2025 Feb;480(2):869-890. doi: 10.1007/s11010-024-05074-1. Epub 2024 Jul 20.
9
Mitochondrial transplantation for ischemic heart disease.
Nat Nanotechnol. 2024 Sep;19(9):1247-1248. doi: 10.1038/s41565-024-01678-2.
10
Dihydromyricetin regulates RIPK3-CaMKII to prevent necroptosis in high glucose-stimulated cardiomyocytes.
Heliyon. 2024 Mar 29;10(7):e28921. doi: 10.1016/j.heliyon.2024.e28921. eCollection 2024 Apr 15.

本文引用的文献

1
Pleiotropic effects of mitochondria in aging.
Nat Aging. 2022 Mar;2(3):199-213. doi: 10.1038/s43587-022-00191-2. Epub 2022 Mar 17.
3
High-frequency and functional mitochondrial DNA mutations at the single-cell level.
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2201518120. doi: 10.1073/pnas.2201518120. Epub 2022 Dec 28.
4
Mitochondria Clumping vs. Mitochondria Fusion in CMT2A Diseases.
Life (Basel). 2022 Dec 15;12(12):2110. doi: 10.3390/life12122110.
5
Preferred Migration of Mitochondria toward Cells and Tissues with Mitochondrial Damage.
Int J Mol Sci. 2022 Dec 12;23(24):15734. doi: 10.3390/ijms232415734.
6
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity.
Trends Pharmacol Sci. 2023 Jan;44(1):34-49. doi: 10.1016/j.tips.2022.10.003. Epub 2022 Nov 14.
7
Mitochondrial Cardiomyopathy: The Roles of mt-tRNA Mutations.
J Clin Med. 2022 Oct 30;11(21):6431. doi: 10.3390/jcm11216431.
9
PCSK9 Knockdown Can Improve Myocardial Ischemia/Reperfusion Injury by Inhibiting Autophagy.
Cardiovasc Toxicol. 2022 Dec;22(12):951-961. doi: 10.1007/s12012-022-09771-5. Epub 2022 Nov 7.
10
ROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways.
Oxid Med Cell Longev. 2022 Oct 19;2022:1225578. doi: 10.1155/2022/1225578. eCollection 2022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验